This popular annual event is now in its 6th year. 

New to this meeting will be a troubleshooting panel session. 
On registration you will be able to submit your questions to the panel that will be asked by the chair on the day of the event

This meeting will have CPD approval from The Institute of Biomedical Scientists (IBMS). 

About the Chair:
Dr Will Howat graduated with a BSC (Hons) in Immunology & Pharmacology from the University of Strathclyde, before gaining a PhD in Pathology from the University of Southampton. After two post-doctoral positions in Southampton, he moved to the Wellcome Trust Sanger Institute in Cambridge as the leader of Research & Development for the Immunohistochemistry group of the Atlas of Protein Expression project. He is now with Cancer Research UK as the head the Histopathology/ISH facility at the Cambridge Research Insititute.

Talks Include:

FISH  techniques and applications
Dr Paul A.W. Edwards, Reader in Cancer Biology,  Department of Pathology, University of Cambridge.
FISH techniques will be reviewed with reference both to recent developments and to current well-established applications

Immunohistochemical Investigation of Lynch / HNPCC syndrome
Dr Mark Arends, University Reader & Hon Consultant University of Cambridge & Addenbrooke’s Hospital, Cambridge, UK
Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome accounts for 2-4% of colorectal cancers and is caused by inheritance of a mutated Mismatch Repair gene, usually MSH2 or MLH1, but occasionally others (e.g. MSH6 or PMS2). This leads to microsatellite instability (MSI) in tumour DNA. Extra-colonic tumours may also develop such as those of endometrium, ureter, ovary, stomach, small intestine, and skin (sebaceous tumours). Suspected HNPCC cases are identified by family history and their tumours examined for abnormal MMR protein expression by immunohistochemistry for MLH1, MSH2, MSH6 and PMS2, with different expression patterns for normal (homogeneously positive) and MMR abnormal (homogeneously or weakly negative) tumours.

Dual fluorescence methods for wholemount and sections
Carrie Ambler, UK

Preparation and uses of frozen tissue microarrays.
Helen Shulver, Asterland UK

How to make a new antibody work for IHC?' And that is what most of us want, isn't it?

Dr Chris van der Loos, Academic Medical Center, Amsterdam, The Netherlands

About the Speakers

Dr Mark Arends trained in Medicine and Pathology at the University of Edinburgh, becoming a Senior Lecturer in the University Department of Pathology and Honorary Consultant at the Royal Infirmary of Edinburgh. He moved to the University of Cambridge in 1999, where he is now a University Reader in Histopathology and Honorary Consultant at Addenbrooke's Hospital. He is lead pathologist for colorectal pathology and gynaecological pathology for Cambridge. His research includes the genomic, genetic and epigenetic mechanisms of colorectal cancer development and progression, including inherited susceptibility to colorectal carcinogenesis.

Dr Paul Edwards has worked on various aspects of breast cancer for thirty years. After an early involvement in monoclonal antibody production he developed methods for genetically manipulating the mouse mammary gland, and for the last decade or so has been developing FISH and array technology to study chromosome rearrangements in breast cancer